Urovant’s new overactive bladder (OAB) drug Gemtesa (vibegron) is approved by the FDA
… Urovant’s New Overactive Bladder Drug Gemtesa (vibegron) is FDA approved …

UROVANT’S NEW OAB DRUG GEMTESA (vibegron) EARNS FDA APPROVAL

John G. Baresky

The approval of Gemtesa is a strategic corporate milestone for Urovant

Gemtesa is an oral pharmaceutical agent that is produced in pill form and available by prescription only. It is a beta-3 adrenergic receptor (β3) agonist. Founded in 2016, it is Urovant’s (NASDAQ: UROV) first new drug approval.

  • Enablex (available as a generic)
  • Vesicare (available as a generic)
  • Toviaz (Pfizer)

Urovant is a business unit of a larger global conglomerate

Urovant is owned by Sumitomo Dainippon Pharma (DSP), a company that was formed upon the completion of a partnership between Roivant Sciences Ltd. And DSP. The Sumitovant BioPharma organization that Urovant belongs to operates 5 pharmaceutical companies; each is highly specialized:

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/